Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32498097    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32498097  :  Publisher

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis #MMPMID32498097
  • Langer F; Kluge S; Klamroth R; Oldenburg J
  • Hamostaseologie 2020[Aug]; 40 (3): 264-269 PMID32498097show ga
  • The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with COVID-19 are at significant risk of thromboembolic complications, mainly affecting the venous, but also the arterial vascular system. While the risk of venous thromboembolism (VTE) appears to be higher in patients requiring intensive care unit support compared to those admitted to general wards, recent autopsy findings and data on the timing of VTE diagnosis relative to hospitalization clearly suggest that thromboembolic events also contribute to morbidity and mortality in the ambulatory setting. In addition to a severe hypercoagulable state caused by systemic inflammation and viral endotheliitis, some patients with advanced COVID-19 may develop a coagulopathy, which meets established laboratory criteria for disseminated intravascular coagulation, but is not typically associated with relevant bleeding. Similar to other medical societies, the Society of Thrombosis and Haemostasis Research has issued empirical recommendations on initiation, dosing, and duration of pharmacological VTE prophylaxis in COVID-19 patients.
  • |Anticoagulants/therapeutic use[MESH]
  • |Autopsy/statistics & numerical data[MESH]
  • |Betacoronavirus/isolation & purification[MESH]
  • |Blood Coagulation Disorders/epidemiology/*etiology[MESH]
  • |COVID-19[MESH]
  • |Case-Control Studies[MESH]
  • |China/epidemiology[MESH]
  • |Coronavirus Infections/*complications/epidemiology/pathology/virology[MESH]
  • |Disseminated Intravascular Coagulation/blood/diagnosis/physiopathology[MESH]
  • |Heparin, Low-Molecular-Weight/therapeutic use[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*complications/epidemiology/pathology/virology[MESH]
  • |SARS-CoV-2[MESH]
  • |Survivors/statistics & numerical data[MESH]
  • |Systemic Inflammatory Response Syndrome/physiopathology/virology[MESH]
  • |Thrombophilia/etiology[MESH]
  • |Venous Thromboembolism/drug therapy/mortality/*prevention & control[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    264 3.40 2020